1. Home
  2. NGNE vs NC Comparison

NGNE vs NC Comparison

Compare NGNE & NC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NGNE
  • NC
  • Stock Information
  • Founded
  • NGNE 2003
  • NC 1913
  • Country
  • NGNE United States
  • NC United States
  • Employees
  • NGNE N/A
  • NC N/A
  • Industry
  • NGNE Biotechnology: Pharmaceutical Preparations
  • NC Coal Mining
  • Sector
  • NGNE Health Care
  • NC Energy
  • Exchange
  • NGNE Nasdaq
  • NC Nasdaq
  • Market Cap
  • NGNE 325.3M
  • NC 286.1M
  • IPO Year
  • NGNE N/A
  • NC N/A
  • Fundamental
  • Price
  • NGNE $18.48
  • NC $39.14
  • Analyst Decision
  • NGNE Strong Buy
  • NC
  • Analyst Count
  • NGNE 7
  • NC 0
  • Target Price
  • NGNE $41.86
  • NC N/A
  • AVG Volume (30 Days)
  • NGNE 110.1K
  • NC 6.0K
  • Earning Date
  • NGNE 08-11-2025
  • NC 10-29-2025
  • Dividend Yield
  • NGNE N/A
  • NC 2.58%
  • EPS Growth
  • NGNE N/A
  • NC N/A
  • EPS
  • NGNE N/A
  • NC 4.23
  • Revenue
  • NGNE N/A
  • NC $265,880,000.00
  • Revenue This Year
  • NGNE N/A
  • NC N/A
  • Revenue Next Year
  • NGNE N/A
  • NC N/A
  • P/E Ratio
  • NGNE N/A
  • NC $9.25
  • Revenue Growth
  • NGNE N/A
  • NC 27.25
  • 52 Week Low
  • NGNE $6.88
  • NC $25.19
  • 52 Week High
  • NGNE $74.49
  • NC $45.50
  • Technical
  • Relative Strength Index (RSI)
  • NGNE 35.93
  • NC 55.37
  • Support Level
  • NGNE $19.59
  • NC $38.48
  • Resistance Level
  • NGNE $20.46
  • NC $39.31
  • Average True Range (ATR)
  • NGNE 1.23
  • NC 1.03
  • MACD
  • NGNE -0.20
  • NC 0.35
  • Stochastic Oscillator
  • NGNE 13.37
  • NC 85.68

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About NC NACCO Industries Inc.

NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments that are coal mining, North American mining (NA mining), and minerals management. The majority of its revenue is from the coal mining segment. This segment operates surface coal mines under long-term contracts with power generation companies and an activated carbon producer pursuant to a service-based business model. The NA mining segment provides value-add contract mining and services for producers. Minerals management generates income from royalty-based leases by acquiring and promoting oil, gas, and coal mineral interests. The company is diversifying beyond coal mining due to political and economic pressures associated with carbon emissions.

Share on Social Networks: